在肺腺癌中IFNG驱动的免疫细胞死亡的分子亚型和治疗向

在肺腺癌中IFNG驱动的免疫细胞死亡的分子亚型和治疗向

相关实验视频

Updated: May 28, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.0K

Lifeng Li^1,2,3,4, Yaqi Yang^1,2, Mengle Peng^5,6

¹National Engineering Laboratory for Internet Medical Systems and Applications, the First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, Henan, China.

Cancer medicine

|February 13, 2025

概括

研究人员确定了肺腺癌 (LUAD) 中的两个新型免疫细胞死亡 (ICD) 分子类型. 一个亚型显示出更好的预后和对化疗的敏感性增加,为个性化的LUAD治疗提供了洞察力.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
基因组学就是基因组学.

背景情况:

免疫细胞死亡 (ICD) 疗法增强抗瘤免疫力,在瘤免疫治疗中至关重要.
了解ICD的作用是提高癌症治疗效率的关键.

研究的目的:

在肺腺癌 (LUAD) 中识别与ICD相关的新型分子亚型.
分析这些亚型的临床意义,瘤微环境和治疗敏感性.
调查干扰素- (IFNG) 在LUAD中的作用.

主要方法:

来自TCGA和GEO的LUAD数据的共识聚类,以定义ICD分子亚型.
在亚型之间对临床特征,基因表达,突变,瘤微环境,免疫检查点和药物敏感性的比较分析.
试验室实验 (RT-qPCR,西斑,免疫光学,ELISA,流细胞计,管形成试验) 验证IFNG的功能.

主要成果:

确定了两种不同的ICD分子亚型,其中集群2在队列中表现出优异的预后.
集群2在临床病理学特征,ICD基因的高表达,驱动基因,免疫检查点和免疫细胞方面表现出显著差异.
集群2显示对化疗药物的敏感性增加. IFNG过度表达促进了ICD,树突细胞成熟,CD8+T细胞功能和血管生成,这些功能可以通过HMGB1抑制来调节.

结论:

在LUAD中与ICD相关的新型分子亚型可以指导个性化疗法,预后评估和免疫疗法疗效预测.
IFNG是一种潜在的预后生物标志物和LUAD的治疗点,影响瘤微环境和血管生成.
研究结果提供了对IFNG介导路径向的LUAD治疗策略的见解.

关键词:

IFNG IFNG 的意思是免疫性细胞死亡免疫性细胞死亡肺部腺癌的癌症.分子子类型分子子类型瘤微环境是一个微环境.

更多相关视频

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

7.9K

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

06:03

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

16.8K

相关概念视频

02:57

Targeted Cancer Therapies

7.4K

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

7.4K

01:27

Tumor Immunotherapy

464

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.